Oncopeptides soon will seek conditional approval of melflufen (melphalan flufenamide) in the EU for the treatment of relapsed or refractory multiple myeloma. The pharmaceutical company now is planning to submit its application — some two years earlier than expected — to the European Medicines Agency (EMA) to request melflufen’s conditional approval. The request was originally intended to be submitted only after the expected mid-2022 completion of OCEAN (NCT03151811), a Phase 3 trial currently investigating whether a combination…
You must be logged in to read/download the full post.
The post Oncopeptides Will Seek Conditional Approval of Melflufen in Europe appeared first on BioNewsFeeds.